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APPARATUS AND METHODS FOR 
MEASURING CHARACTERISTICS OF 
BIOLOGICAL TISSUES AND SIMILAR 
MATERIALS 
2 
material under examination is achieved by using the inten-
sity or other characteristics of the unshifted scattered, 
reflected, or otherwise modified beam. In the simplest of 
systems, the normalization is accomplished by using the 
This application is a continuation-in-part of application 
Ser. No. 07/731,533 (now U.S. Pat. No. 5,203,328), filed Jul. 
5 ratio of the emission intensity to the scattered or reflected 
intensity. 
17, 1991, entitled "Apparatus and Methods for Quantita-
tively Measuring Molecular Changes in the Ocular Lens," 
now U.S. Pat. No. 5,203,328 which application is incorpo- 10 
rated herein in its entirety by this reference. 
This invention relates to the measurement of the char-
acteristics of biological tissues and similar materials and 
more specifically to apparatus and methods for quantita-
tively measuring spectral characteristics of human tissue for 15 
the purpose of medical evaluation. 
The process of normalization can be improved further by 
the use of a confocal arrangement with a wide cone between 
the receiver and the pump beam. If the pump beam is 
directed into the tissue via a focusing arrangement with a 
wide focusing cone and a small focal volume and the 
receiver field of regard is limited to the small focal volume, 
the normalization is further improved. If the media to be 
characterized is a human eye, the receiver is preferably 
slightly off axis from the axis of the pump beam so as to 
eliminate specular reflections from the received signal and 
improve the effects of the normalization. 
BACKGROUND OF THE INVENTION It is therefore an object of the present invention to provide 
apparatus and methods for normalization of various spec-
20 troscopic techniques for accurate use in biological tissues 
and other turbid media. 
Existing methods of spectral examination of biological 
tissues and other turbid media are often less than desirable. 
These methods fail to properly normalize for variations in 
the density, scattering, reflectivity, absorbance and transmit-
tance of such tissues and as a result, have wide variations in 
the results obtained. Typically, spectral transmittance, fluo- 25 
rescence (normal and time resolved) and Raman spectros-
copy are used to evaluate biological tissues and other 
materials in order to determine the materials present and 
measure their concentrations. Each of these methods are 
affected by the scattering, reflecting, absorbing and trans- 30 
mitting properties of the media since the amount of light 
reaching the tissue is a function of these parameters and in 
the case of fluorescence and Raman emissions, reabsorption 
of emission spectra. 
In our pending patent application Ser. No. 071731,533, we 35 
discussed the use of new normalization techniques for the 
detection of cataracts and diabetes. In addition, we are aware 
of a patent by Schiller, German Patent#261957Al and R.R. 
Alfano, U.S. Pat. No. 4,930,516 (which patents are incor-
porated herein in their entireties by this reference), which 40 
refer to the use of the ratio between two fluorescence peaks 
in fluorescence spectroscopy as normalization techniques. 
However, since both the target spectra and the reference 
spectra are affected by scattering and absorption, these 
techniques are not wholly satisfactory. 
SUMMARY OF THE INVENTION 
45 
It is another object of the present invention to provide 
apparatus and methods suitable for compensating for scat-
tering and density differences encountered when making 
measurements in turbid media. 
It is yet another object of the present invention to provide 
apparatus and methods for eliminating the effects of specular 
reflections from media with highly reflective boundary lay-
ers, such as the human eye. 
It is a further object of the present invention to provide 
apparatus and methods for determining characteristics of 
tissue, including ones related to the level of glycation in the 
tissue or in other tissues such as the blood. 
It is a further object of the present invention to provide 
apparatus and methods for determining characteristics of 
tissue, including ones related to the level of glycation in the 
tissue or in other tissues such as the blood. 
Other objects, features and advantages of the present 
invention will become apparent with reference to the 
remainder of the written portion and drawings of this 
application. 
BRIEF DESCRIPTION OF THE INVENTION 
FIG. 1 is a schematic representation of an apparatus of the 
present invention. 
FIG. 2 is a graphical representation of an example of the 
50 fluorescent signal intensity obtained using the apparatus of 
FIG. 1. 
The present invention provides apparatus and methods for 
characterizing biological tissues and other turbid media with 
normalization that serves to compensate for the effects of 
scattering, reflectance, and absorption. Utilizing a beam of 
electromagnetic or other radiation directed into the tissue or 
other media to be examined, the pump beam, (preferably a 
beam of optical radiation at a wavelength between 400 55 
nanometers and 20,000 nanometers) and a suitable detector 
directed toward the volume of the tissue or other material to 
60 
be characterized, the receiver, a measurement is made of the 
amount of the pump beam returned to the receiver by effects 
such as scattering, reflection, or other similar effects. A 
measurement is also made of the physical parameter of 
interest, which could be transmission or emission. Emission, 
such as Raman emission or fluorescence emission is typi-
cally at a wavelength offset by the pump beam by an amount 
and intensity dependent on the particular chemical proper- 65 
ties of the material. Other methods, such as time-resolved 
spectroscopy could also be used. Normalization of the 
FIG. 3 is a graphical representation of an example of the 
ratio of the fluorescent to backscattered signal intensities as 
measured in the lens of a human eye (turbid media) using the 
apparatus of FIG. 1. 
FIG. 4 is a graphical representation of the mathematical 
relationship between fluorescence and Hemoglobin Ale. 
FIG. lA is a schematic representation of a prototype 
system in accordance with the present invention. 
FIG. 2A is a schmetic representation of an alternative 
prototype system in accordance with the present invention. 
FIGS. 3A and 4A are graphical representations of data 
obtained using an excitation wavelength of 406.7 nm. 
FIG. SA is a graphical representation of data on fluores-
cence ratios obtained using an excitation wavelength of 
441.6 nm. 
5,582,168 
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FIG. 6 is a graphical representation of data and a proposed 
mathematical model of age dependence of the fluroescence 
ratio. 
FIG. 7 is a graphical representation of the model proposed 
in connection with FIG. 6 as compared with data measured 5 
from a diabetic population. 
FIG. 8 is a graphical representation of Ale levels versus 
age corrected fluorescence ratios of both the diabetic and 
4 
Type I diabetes is essentially an auto-immune disease in 
which the immune system attacks the insulin producing islet 
cells in the pancreas. Because of this, early detection of Type 
I diabetes is possible in some patients, through the use of a 
complex test for antibodies to the pancreatic islet cells. (Islet 
Cell Antibody test or ICA). Unfortunately, standardization 
of the ICA test is not yet sufficient for most diabetologists to 
prescribe it routinely. However, when the ICA test has been 
applied properly, a model developed by Jackson et. al. has control populations. 
DETAILED DESCRIPTION 
10 shown that it can detect a prediabetic condition of Type I 
diabetes several years before overt clinical symptoms of the 
disease are present. One of the most provocative results of 
the work described here, is its' apparent ability to detect this FIG. 1 illustrates a schematic layout of the present inven-
tion. The FIG. 1 shows a illuminating source 20, which is 
directing electromagnetic radiation into the media to be 15 
examined 10. A collecting, separating and detecting means 
30, is shown oriented toward the media to be examined 10. 
A processing means is shown for determining the math-
ematical relationship between the separated radiation 40. 
Further information concerning the subject matter of the 
present invention can be obtained from the following article 
authored by two of the named inventors (J. Eppstein & S. 
Bursell, "Non-invasive detection of diabetes mellitus"): 
Recent advances in fluorescence spectroscopy of the lens 
reveal the potential of a non-invasive device and method-
ology to sensitively measure changes in the lens of the eye 
associated with diabetes mellitus. The system relies on the 
detection of the spectrum of fluorescence emitted from a 
selected volume (approximately 1/10 mm3 ) of the lens of 
living human subjects using low power excitation illumirn,1-
tion from monochromatic light sources. The sensitivity of 
this technique is based on the measurement of the fluores-
cence intensity in a selected region of the fluorescence 
spectrum and normalization of this fluorescence with respect 
prediabetic condition when no other symptoms are present. 
Another blood test which is routinely prescribed for 
diagnosed diabetic patients is a measure of the serum 
hemoglobin Al c levels. Measuring the glycosylation of the 
patients hemoglobin, this test gives the clinician a quanti-
tative measure of how well the patient has controlled their 
20 blood glucose levels over the last 6 to 10 weeks. The Ale 
test is routinely prescribed every one to three months for 
most type I diabetic patients and at least twice a year for 
most type II diabetic patients. The Ale test is generally 
accepted as the best indicator of the efficaciousness of a 
25 prescribed treatment regimen for a diabetic. Upon initial 
diagnosis, the Ale test is used even more frequently to fine 
tune a treatment program. A definite correlation has been 
observed between the fluorescence ratio measurements 
made with the system and a diabetic subject's Ale levels. A 
30 model for estimating the Ale level as a function of age and 
Fluorescence/Rayleigh Ratio has been developed. 
The prototype system utilizes a low power laser to excite 
to attenuation (scattering and absorption) of the incident 35 
excitation light. The amplitude of the unshifted Rayleigh 
line, measured as part of the fluorescence spectrum, is used 
a fluorescent response in a small volume of the ocular lens 
tissue. A schematic representation of this system is shown in 
FIG. lA. The system allows the illumination source to be 
selected from lasers emitting at 406.7 nm, 441.6 nm, 488 
nm, or 514.5 nm. An optical collection system, aligned 
confocally with the illumination system, is used to gather the 
entire spectrum of the fluorescence response as well as the 
backscattered Rayleigh radiation from the lens. The optical 
design of the system is such that specular reflections of the 
as a measure of the attenuation of the excitation light in the 
lens. Using this methodology we have demonstrated that the 
normalized lens fluorescence provides a more sensitive 40 
discrimination between diabetic and non-diabetic lenses 
than more conventional measurements of fluorescence 
intensity from the lens. The existing instrumentation will be 
described as well as the proposed design for a commercial 
version of the instrument expected to be ready for FDA trials 
by late 1992. The results from clinical measurements are 
used to describe a relationship between normalized lens 
fluorescence and hemoglobin A le levels in diabetic patients. 
1. INTRODUCTION 
incident light from the cornea and lens capsule are excluded 
from the collection system. The collection optics also pro-
vide the operator with an eyepiece through which the 
45 operator views the area in the lens which is currently being 
targeted. The collected light, both emitted fluorescence and 
backscattered excitation light, is delivered to a spectrometer 
which focuses the spectrum onto an intensified diode array 
detector. The intensity spectrum of the emitted fluorescence 
50 is thus recorded together with the unshifted Raleigh com-
ponent for subsequent processing. 
The emitted fluorescence in a defined spectral region is 
normalized using the amplitude of the unshifted Rayleigh 
55 components. This fluorescence ratio provides a good dis-
crimination between lenses of diabetic and non-diabetic 
subjects. 
Over the last two decades, a good deal of research has 
been done to characterize the fluorescent response of the 
human lens. Researchers have searched to uncover correla-
tions between detected shifts in the lens' optical properties 
and the physiological condition of the subject under test. 
Previous research has established some correlation between 
the fluorescent response of the lens and the subjects age and 
the presence of diabetes. The work described in this paper 
continues in this direction, with the focus being to refine the 60 
apparatus and method such that a non-invasive test for the 
detection of diabetes mellitus becomes possible. 
In the case of Type I, or juvenile diabetes, early detection 
can significantly benefit the patient. Some research has 
indicated that if detected early enough, the onset of full 65 
blown Type I diabetes maybe delayed for several years with 
new developments in immunosuppressive drug therapy. 
2. METHODS 
2.1 Instrumentation 
A unique optical system has been devised which allows 
the user to selectively target small volumes within the lens 
for excitation with a light source. The laser light used in this 
system is directed through a variable optical attenuator (A) 
and then focused onto the end of a 140 micrometer fiber 
optic. The fiber optic routes the laser light to the delivery 
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optics (L2). Using a modified slit lamp base to support both 
the delivery optics (L2) and collection optics (L3), a con-
focally aligned collection system allows this same small 
volume to be examined. An eyepiece (E) allows the operator 
to view directly the area being targeted. A fiber optic bundle 5 
positioned in the collection optics carries the collected light 
to a spectrometer (S) which is in turn connected to a 
computer controlled data acquisition system. 
Both the backscattered Rayleigh radiation and the excited 
fluorescent radiation being emitted from the targeted volume 10 
within the lens are collected and directed into the spectrom-
eter with its enhanced diode detector array (D). The rela-
tively large focal cone of both the delivery and the collection 
optics, and the small spot size illuminated and imaged, 15 
allows the operator to easily distinguish the boundaries at 
both the anterior and the posterior of the lens merely by 
observing the visual change in the image as seen through the 
eyepiece. 
A position sensor attached to the modified slit lamp allows 20 
the automatic registration of the position in the lens from 
which a given spectrum was recorded. The operator, under 
direct visualization, marks both the anterior and posterior 
lens capsule positions along the visual axis, within the lens, 
and the position from which each spectrum was taken is 25 
recorded. 
The instrument can be used on either dilated or undilated 
eyes. When used on undilated subjects, closer attention must 
be made to the positioning of the instrument to exclude the 
possibility of collecting a specularly reflected component of 30 
the source if it were to hit the iris. To verify the useability 
6 
2.2 Patient Measurement Protocol 
Prior to patient measurements the level of the incident 
excitation illumination is set using fluorescence measure-
ments from a fluorescent glass standard. The incident illu-
mination is adjusted using a variable attenuator in the path 
of the laser beam. The source intensity is set to provide a 
fixed level of fluorescence intensity which corresponds to an 
illumination power level of less than 500 microwatts of 
continuous power. 
The subject is then seated at the slit lamp and asked to 
position their head in the head rest provided and look at the 
fixation target. The operator, while directly viewing the lens 
through the eyepiece, brings the focal plane of the viewing 
and illumination optics into the central region of the lens of 
the eye by adjusting the position of the slit lamp. The 
fixation target is then adjusted to ensure that specular 
reflections from the cornea and lens capsule are excluded 
from the collection optics. The anterior and posterior capsule 
boundaries are marked using the position sensor attached to 
the slit lamp as it is scanned along the visual axis of the lens. 
Having located the positions of the front and rear of the lens 
the operator then scans along the visual axis of the lens 
selecting points from which fluorescence spectra are 
recorded. The positions at which each spectra were obtained 
are also recorded. Typically, 10 spectra are recorded along 
this visual axis. The exposure time required for each spec-
trum is 2 seconds. This time was chosen as a compromise 
between excitation light exposure, signal-to-noise ratio of 
the recorded spectra and the time during which a subject 
could comfortably keep their eye open without blinking. 
2.3 Data Analysis 
The total fluorescence emitted from a region in the lens, 
at a given excitation intensity, can be affected by absorption 
and scattering attenuation, not only of the incident excitation 
of the instrument on undilated subjects, several subjects 
have been measured twice, once dilated and once undilated, 
and the results have been shown to be the same. This is 
important for any non-invasive testing device. 
The prototype instrument can easily be modified to pro-
vide a portable instrument with commercial potential. Hav-
ing determined which wavelength to use for the source and 
which portion of the recorded spectrum to examine to 
measure the fluorescent response, it is possible to design a 
much simpler, dedicated system, capable of making the 
same measurement. This is illustrated in FIG. 2A. By using 
custom optics to both deliver (20' and 40') and collect (60) 
the light, one achieves a direct optical path through optical 
filters (110) and dichroic beam splitters (70 and 90) to 
discrete photo-detectors (100 and 120). In comparison to the 
prototype's fiber coupled spectrometer and diode array, 
optical efficiency may be increased by several orders of 
magnitude. 
35 but also of the emitted fluorescence. Increases in scattering 
will decrease the available excitation energy delivered to the 
sample region of the lens and decrease the emitted fluores-
cence intensity collected by the collection optics. Increased 
absorption in front of the sample region will also decrease 
40 the delivered excitation energy and the emitted fluorescence 
intensity. Thus when comparing two lenses, for example, 
both having the same concentration of lens fluorophore but 
with one lens being more highly scattering than the other, the 
lens exhibiting the higher scattering will show an apparent 
45 decrease in fluorescence intensity compared to the less 
scattering lens. 
The attenuation effects of lens scattering and lens absorp-
tion can be corrected for by normalizing the emitted fluo-
rescence with respect to the actual intensity of incident 
50 excitation illumination delivered to the sample region. Thus, 
forming the ratio between the fluorescence intensity and the 
Rayleigh intensity provides a normalization of the fluores-
cence intensity. This fluorescence ratio thus provides a basis 
With this increase in detection efficiency, the source 
intensity may be correspondingly lowered, thereby relaxing 
the requirement that a laser be used for the source. Design 
analysis has shown that a low power, short arc lamp, with 
appropriate optics and an optical filter can provide enough 
optical power. Other sources being investigated include laser 55 
diodes (10') coupled to frequency doubling device (30'), blue 
LEDs and filtered, special purpose incandescent lamps. To 
exclude specular reflections from the detectors, polarization 
filters are proposed for both the transmit and receive optics. 
for quantitative comparisons between different lenses. 
Further specificity in analyzing lens fluorescence is real-
ized by analyzing specific spectral regions of the recorded 
spectra. It has been demonstrated that the aging lens contains 
a number of different fluorescing proteins exhibiting fluo-
rescence at longer and longer excitation wavelengths. For 
The electronics associated with the detection and process-
ing (130) consist of the two analog preamps used with the 
detectors, and a single chip microcontroller equipped with 
onboard analog to digital (AID) conversion. Embedded 
firmware would direct the operator through a measurement 
event and then either display the processed measurement 
information on the systems own digital display, or log this 
data to a computer via a serial interface. 
60 example, in older lenses and brunescent cataracts there 
exists a significant red fluorescence. By restricting the 
spectral region from which fluorescence measurements are 
made, at a given excitation wavelength, it is possible to 
isolate the characteristics of a relatively distinct species of 
65 lens protein fluorophores. 
The effectiveness of our lens fluorescence normalization 
procedure was tested by scanning through the glass fluores-
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cence standard at the different excitation wavelengths used. 
The fluorescence ratio remained constant (±5%) through the 
glass despite significant absorption as noted by a 3-fold 
reduction in the intensity of the Rayleigh line and a con-
comitant reduction in the measured fluorescence intensity. 5 
At each excitation wavelength used 406.7 nm, 441.6 nm, 
488 nm, and 514.5 nm, the measured fluorescence spectra 
from the lens exhibited intensity maxima in the 490 nm, 520 
nm, 540 nm, and 550 nm wavelength regions respectively. 
Analysis involved calculating the fluorescence ratio using 10 
average fluorescence in a 10 nm spectral region centered 
about the wavelength at which the fluorescence intensity 
maximum occurred. The fluorescence ratio is defined as the 
ratio of this fluorescence to the intensity of the backscattered 
Rayleigh component. The data presented in this paper are 15 
the average of the fluorescence ratios obtained from the lens 
nucleus. 
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newborn, no fluorescence response would be expected, as 
the lens is almost 100% transmissive at 406.7 nm. The rate 
of increase in the fluorescence versus age would be expected 
to increase most rapidly over the first 20 years, by which 
time the lens is now absorbing 70% to 80% of light at 406. 7 
nm. This trend would then be expected to increase more 
gradually for the remaining 60 years, proportional to the 
continued gradual increase in absorption. 
A quadratic model to describe F/R{AGE}, at 406.7 nm, 
has been derived from the control population data and the 
assumptions made by inference from the lens transmittance 
data. Also, the assumptions that additional limiting factors 
will come into play as one ages, and that the age dependency 
can be decoupled from other factors affecting the FIR have 
been incorporated into the derivation of the model presented 
here. 
FIR(AGE)=0.3S(AGE)--0.0023(AGE)2 
3. RESULTS 
A graph of the raw data and the proposed model is presented 
20 in FIG. 6. 
This relationship was obtained by setting boundary values 
on the two end points ofFIR(O)=O and FIR(80)=16, and then 
applying a second order regression to fit the resulting curve 
to the control data in a least squares sense. This model meets 
The data presented here were obtained using excitation 
wavelengths of 406.7 nm and 441.6 nm. The capability of 
measuring fluorescence spectra at the longer excitation 
wavelengths has only recently been incorporated into the 
instrumentation and clinical measurements are currently in 
progress. 
25 the criteria of starting at zero, rising most rapidly in the first 
20 years, and then approaching a final limiting value more 
gradually over the next 60 years. By deriving this model on 
the data taken from only the control population and the 
assumptions stated, a rough test of its' validity can be made 
The data obtained using the 406. 7 nm excitation wave-
length is illustrated in FIGS. 3A and 4A. FIG. 3A illustrates 
the fluorescence ratio data, using the fluorescence intensity 
emitted in the 490 nm region of the spectrum detected versus 
subject age for both diabetic and non-diabetic subjects. As 
can be noted there is a marked separation between the 
diabetic and non-diabetic subject's fluorescence ratios. In 
contrast, FIG. 4A illustrates the same data except that the 35 
total emitted fluorescence was calculated by integration of 
the recorded spectrum and the fluorescence intensity was not 
normalized with respect to the delivered excitation energy. 
30 by applying it to those data points measured from the 
diabetic population used in this study and evaluating the 
shift in the correlation coefficient. This is shown in FIG. 7. 
Before the model was applied, the correlation coefficient 
In this case, for the same subjects as in FIG. 3A, the 
distinction between diabetic and non-diabetic lenses is con- 40 
siderably less remarkable. 
between the FIR and the subjects age was shown to be 
(0.5355), after the hypothesized age dependency was sub-
tracted from the data, the resulting data set showed a 
correlation coefficient between the FIR{AGE_COR-
RECTED} and the subjects age to be (0.0748). This reduc-
tion of the correlation coefficient confirms, to some degree, 
the correctness of the model. An additional validation of this 
model and the assumption of independence is provided 
when the relationship between the Ale levels and the FIR is 
examined in the following section. 
FIG. 5 shows the data on fluorescence ratios obtained 
using the 441.6 nm excitation wavelength. In this case the 
increase in lens fluorescence ratio with age is more marked, 
however, the discrimination between diabetic and non-
diabetic lenses is less pronounced in subjects less than 40 
years old compared to the results obtained using 406.7 nm 
excitation wavelength. 
3.2 Correlation of hemoglobin Ale and the fluorescence 
45 ratio at 406.7 nm 
Comparing FIGS. 3A and SA also illustrates how the 
406.7 nm excitation wavelength (FIG. 3A) produced fluo- 50 
rescence ratios of the three (3) subjects who tested !CA 
positive, but otherwise have no diabetic symptoms, which 
groups them with the diabetic subjects. Conversely, the 
441.6 nm excitation wavelength (FIG. 5) produced fluores-
cence ratios which group these three (3) subjects within the 55 
non-diabetic control population. 
3.1 Age dependence of the fluorescence ratio at 406.7 nm 
Studies of the human lens have shown a definite age 
dependant component of the lens' transmission at all wave-
lengths from 300 nm to 800 nm. (Lerman, Hockman 1981; 60 
Lerman, Hockman, Ohrloff, 1984). At the specific wave-
length of 406.7 nm, it has been shown that the lens' 
transmittance drops from almost 100% in a newborn to 
about 25% by the age of 25. While the exact relation 
between absorption at 406.7 nm and the fluorescence 65 
response to that wavelength is not known, some trends can 
be inferred from our knowledge of transmittance. For a 
An apparent correlation between the Ale levels and a 
subjects FIR values could be discerned for the diabetic 
population for whom the Ale data was available. 
To develop a model for estimating the underlying rela-
tionship between Ale and FIR the following assumptions 
were made: 
a.) The age dependent component of the FIR is completely 
disjointed from the Ale dependent component. This 
assumption is confirmed to some degree by the observed 
increase in the correlation coefficient (increased to 0.6385 
for the age corrected data from 0.465 for the measured data) 
relating both the age corrected and the measured FIR to the 
Ale levels of the diabetic population. This increase in the 
correlation coefficient also provides further validation of the 
model derived from F/R{age }, i.e., if the model was inher-
ently incorrect, applying it would redistribute the data such 
that any other correlations would be made more difficult to 
uncover. 
b.) All of the control population have Ale levels failing 
within a 'normal' range of between 3 and 7. (Diabetologists 
typically assume that the upper limit for Ale in a non-
diabetic is 6.2 and a practical lower limit is around 3.5) 
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c.) That the shifts in Ale levels are proportional to the 
shifts in F/R. 
10 
The usefulness of the device is apparently closely tied to 
the specific excitation wavelength used. In particular, the 
two graphs shown in FIGS. 3A and 5 illustrate the difference 
in specificity provided by a 406. 7 nm source versus a 441.6 
Applying assumption (b) a random number generator was 
used to arbitrarily assign Ale values to the control popula-
tion with a normal distribution centered at 5 and having a 
variance of 2. FIG. 8 illustrates this data. The horizontal axis 
shows the Age corrected FIRs of both the diabetic and the 
control populations while the vertical axis shows the Ale 
levels for each subject. The correlation coefficient for the 
data shown in FIG. 8 was found to be (0.89). A linear 
regression was then applied to fit a straight line approxima-
tion for the relationship between the age corrected FIR and 
the Ale level to this data. The resulting relationship is: 
5 nm source, when attempting to distinguish a diabetic from a 
non-diabetic subject. These data also illustrate the potential 
of the 406. 7 nm excitation wavelength to identify the three 
(3) subjects who tested ICA positive, but otherwise have no 
diabetic symptoms, as a diabetic. Conversely, the 441.6 nm 
Alc{FIR{AGE_CORRECTED} }=6+-0.4255(FIR{AGE_COR-
RECTED} 
10 excitation wavelength classifies these three (3) subjects well 
within the non-diabetic control population. While three (3) 
data points are insufficient to state conclusively the ability to 
detect this prediabetic condition, the possibility of such a test 
is extremely exciting. More subjects are currently being 
measured to establish more precisely the specificity of this 
Whereas FIR {AGE_ CORRECTED}=FIR-FIR(AGE)=F/ 
R-[0.38(AGE)-0.0023(AGE)2] we have 
15 system for detecting diabetes. Preliminary results at the 
longer excitation wavelengths of 488 nm and 514.5 nm look 
promising. 
Alc{F/R,AGE}=6+(0.4255)(F/R)-(0.162)(AGE)+(0.00098)(AGE)2 20 
4. DISCUSSION AND CONCLUSION 
Results to date demonstrate that the specificity of lens 25 
fluorescence normalization using a selected spectral band-
width from the emitted lens fluorescence spectrum provides 
a sensitive non-invasive technique for evaluating changes in 
the lens fluorescence associated with diabetes. 
The age dependence of increasing fluorescence ratio at 30 
406.7 nm excitation wavelength appears to level off after 
approximately age 40. In contrast the age dependence of 
fluorescence ratios at 441.6 nm excitation wavelength 
appear to be relatively level in subjects under age 40 with an 
accelerated increase with age in older subjects. This phe- 35 
nomenon may be related to the internal conversion of shorter 
wavelength excitation lens fluorophores to longer wave-
length excitation species in the aging lens. Thus the accu-
mulation with age of the species excited primarily at 406.7 
nm is offset by a decrease in their concentration as they are 40 
converted into longer wavelength excitation species, as 
evidenced in the increasing concentration of the 441.6 nm 
excitation species with age. 
While variances occur in the absolute values of the 
detected fluorescence and backscattered Rayleigh compo- 45 
nents along the radial axis of the lens, when the ratio is 
formed the normalization which occurs nulls these differ-
ences. By design, the delivery and collection optics are 
focused on the same point in space. The intersection of the 
focal waists define a volume of approximately 0.12 mm3 • 50 
Also, both the instrumentation and the methodology has 
been designed to eliminate specular reflections from being 
collected. Thus the Rayleigh component collected can be 
used as a measure of the total optical energy delivered to the 
sampled volume. This feature removes the effect of the 55 
variances of absolute energies caused by individual differ-
ences in the cornea, the aqueous or the lens itself. At these 
power levels, the fluorescent response is proportional to the 
amount of stimulus available. Therefore, the ratio of the 
collected fluorescent and Rayleigh components provides a 60 
repeatable, normalized, and dimensionless measurement of 
the lens' optical properties. Furthermore this type of Ray-
leigh normalization appears to be applicable at all excitation 
wavelengths examined so far. The importance of this tech-
nique is shown in FIGS. 3A and 4A wherein the difference 65 
between the total fluorescence and the normalized fluores-
cence can clearly be seen. 
The foregoing is provided for purposes of illustration, 
explanation, and description of embodiments of the present 
invention. Modifications and adaptations to these embodi-
ments will be apparent to those of ordinary skill in the art 
and may be made without departing from the scope or spirit 
of the invention. 
We claim: 
1. An apparatus for determining the normalized charac-
teristics of biological tissue or other medium comprising: 
a. means for illuminating the medium with electromag-
netic radiation directed into the medium, thereby caus-
ing the medium to react with a first action selected from 
the group consisting of reflecting, backscattering, trans-
mitting, and emitting responsive radiation and a second 
action selected from the same group excluding the first 
action; 
b. means for collecting the responsive radiation; 
c. means, connected to the collecting means, for separat-
ing the collected radiation into a plurality of compo-
nents; and 
d. means, connected to the separating means, for (i) 
measuring the intensity of each of the separated plu-
rality of components and (ii) determining a mathemati-
cal relationship between the separated plurality of 
components. 
2. An apparatus according to claim 1 in which the 
illuminating means comprises: 
a. a light source selected from the group consisting of 
lasers, laser diodes, laser diodes coupled to nonlinear 
frequency doubling devices, light emitting diodes and 
broadband sources coupled to optical filters; 
b. a lens, optically responsive to the light from the light 
source, for focusing the light; and 
c. a lens system, optically responsive to the focused light, 
having a focus, and defining an aperture at its focus of 
less than approximately 1 cm. 
3. An apparatus according to claim 1 in which the 
illuminating means causes the medium to react by emitting 
responsive radiation, further comprising means for measur-
ing the time difference between illumination of the medium 
and emission of the responsive radiation. 
4. An apparatus for determining the normalized charac-
teristics of biological tissue or other medium comprising: 
a. means for illuminating the medium with electromag-
netic radiation directed into the medium, thereby caus-
ing the medium to react by emitting responsive radia-
tion, which emitted responsive radiation is selected 
from the group consisting of fluorescence emission and 
Raman emission; 
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b. means for collecting the responsive radiation; 
c. means, connected to the collecting means, for separat-
ing the collected radiation into a plurality of compo-
nents; and 
d. means, connected to the separating means, for (i) 5 
measuring the intensity of each of the separated plu-
rality of components and (ii) determining a mathemati-
cal relationship between the separated plurality of 
components. 
12 
e. means, using the responsive radiation, for determining 
the level of glycation. 
11. An apparatus according to claim 10 in which the 
medium comprises ocular tissue and the glycation level 
determining means comprises means for relating the level of 
glycation in the ocular tissue to the amount of hemoglobin 
in the blood affected by the presence of glucose. 
5. An apparatus according to claim 4 in which the 
separating means comprises at least one dichroic beam 
splitter. 
6. An apparatus according to claim 5 in which the 
measuring and determining means comprises at least cine 
single chip detector and the wavelengths of the separated 15 
plurality of components are between approximately 430 to 
20,000 nanometers. 
12. A method for measuring the characteristics of bio-
logical tissue or other medium that, when illuminated, is 
capable of reacting by emitting radiation and with an action 
10 
selected from the group consisting of reflecting, backscat-
tering, and transmitting radiation including Raman and 
Fluorescent components of determinable intensities and 
emission lifetimes, comprising the steps of: 
7. An apparatus according to claim 6 in which the 
illuminating means further comprises means for adjusting 
the illuminating electromagnetic radiation. 20 
8. An apparatus according to claim 4 in which the 
illuminating means includes means for illuminating the 
medium with electromagnetic radiation of more than one 
wavelength. 
9. An apparatus for determining the normalized charac- 25 
teristics of biological tissue or other medium comprising: 
a. means for illuminating the medium with electromag-
netic radiation directed into the medium, thereby caus-
ing the medium to react with an action selected from 
30 the group consisting of reflecting, backscattering, trans-
mitting, and emitting responsive radiation; 
b. means for collecting the responsive radiation; 
c. means, connected to the collecting means, for separat-
ing the collected radiation into a plurality of compo- 35 
nents; 
a. illuminating the medium with electromagnetic radia-
tion, thereby causing the medium to emit radiation and 
react with an action selected from the group consisting 
of reflecting, backscattering, and transmitting respon-
sive radiation; 
b. separating the emitted radiation into its Fluorescent and 
Raman components; 
c. measuring at least two values, including at least one of 
the intensity and emission lifetime of at least one of the 
separated components; and 
d. forming a mathematical relationship between at least 
two of the measured values. 
13. A method according to claim 12 in which the illumi-
nating means comprises the steps of: 
a. providing a light source selected from the group con-
sisting of lasers, laser diodes coupled to nonlinear 
frequency doubling devices, light emitting diodes, and 
broadband sources coupled to optical filters; and 
b. focusing the light using a lens system having a focus 
and defining an aperture at its focus less than 1 cm and 
further comprising the step of comparing the ratio of 
the detected emitted intensities to the backscattered 
intensities for the purpose of diagnosing disease. d. means, connected to the separating means, for (i) 
measuring the intensity of each of the separated plu-
rality of components and (ii) determining a mathemati-
cal relationship between the separated plurality of 
components; and 
14. A method according to claim 13 in which the medium 
has a biochemical composition and the illuminating step 
comprises illuminating the medium with electromagnetic 
40 radiation of more than one wavelength, for diagnosing 
disease and determining the biochemical composition of the 
medium. e. means, using the measured intensities of the plurality of 
separated components, for diagnosing the condition of 
the medium for the purpose of making a medical 
diagnosis, the diagnosing means comprising means for 45 
detecting diabetes. 
10. An apparatus for determining the normalized charac-
teristics of biological tissue or other medium having a level 
of glycation comprising: 
a. means for illuminating the medium with electromag- 50 
netic radiation directed into the medium, thereby caus-
ing the medium to react with an action selected from 
the group consisting of reflecting, backscattering, trans-
mitting, and emitting responsive radiation, which illu-
55 minating means includes means for illuminating the 
medium with electromagnetic radiation of more than 
one wavelength; 
b. means for collecting the responsive radiation; 
c. means, connected to the collecting means, for separat- 60 
ing the collected radiation into a plurality of compo-
nents; 
d. means, connected to the separating means, for (i) 
measuring the intensity of each of the separated plu-
rality of components and (ii) determining a mathemati- 65 
cal relationship between the separated plurality of 
components; and 
15. An apparatus for determining the normalized charac-
teristics of biological tissue comprising: 
a. means, comprising a pump beam, for illuminating the 
biological tissue with optical radiation having a wave-
length of between approximately 40-20000 nanom-
eters and thereby causing the tissue to react with an 
action selected from the group consisting of reflecting, 
backscattering, transmitting, or emitting responsive 
radiation; 
b. means for collecting the responsive radiation; 
c. means, connected to the collecting means, for separat-
ing the responsive radiation into a plurality of compo-
nents; and 
d. means, connected to the separating means, for (i) 
detecting the intensity of each of the plurality of 
components and (ii) determining a specified math-
ematical relationship between the plurality of compo-
nents. 
16. An apparatus according to claim 15 in which the 
illuminating means further comprises a confocal arrange-
ment having a wide focusing cone and a small focal volume. 
17. A method for determining the normalized character-
istics of biological tissue or other medium comprising the 
steps of: 
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a. illuminating the medium with electromagnetic radiation 
directed into the medium, thereby causing the medium 
to react with a first action selected from the group 
consisting of reflecting, backscattering, transmitting, 
and emitting responsive radiation and a second action 5 
selected from the same group excluding the first action; 
b. collecting the responsive radiation; 
c. separating the collected radiation into a plurality of 
components; and 
d. measuring the intensity of each of the separated plu-
rality of components and determining a mathematical 
relationship between the separated plurality of compo-
nents. 
10 
18. An apparatus for determining the normalized charac- 15 
teristics of biological tissue or other medium comprising: 
a. means for illuminating the medium with electromag-
netic radiation directed into the medium, thereby caus-
ing the medium to backscatter radiation and react with 
an action selected from the group consisting of reflect- 20 
ing,. transmitting, and emitting responsive radiation; 
b. means for collecting the responsive radiation; 
c. means, connected to the collecting means, for separat-
ing the backscattered radiation from the remainder of 
14 
the collected radiation to define a plurality of compo-
nents; and 
d. means, connected to the separating means, for measur-
ing the intensity of each of the separated plurality of 
components and determining a mathematical relation-
ship between the separated plurality of components. 
19. A method for determining the normalized character-
istics of biological tissue or other medium comprising the 
steps of: 
a. illuminating the medium with electromagnetic radiation 
directed into the medium, thereby causing the medium 
to backscatter radiation and react with an action 
selected from the group consisting of reflecting, trans-
mitting, and emitting responsive radiation; 
b. collecting the backscattered and responsive radiation; 
c. separating the backscattered radiation from the remain-
der of the collected radiation to define a plurality of 
components; and 
d. measuring the intensity of each of the separated plu-
rality of components and determining a mathematical 
relationship between the separated plurality of compo-
nents. 
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